Country: Canada
Language: English
Source: Health Canada
SELEGILINE HYDROCHLORIDE
AA PHARMA INC
N04BD01
SELEGILINE
5MG
TABLET
SELEGILINE HYDROCHLORIDE 5MG
ORAL
15G/50G
Prescription
MONOAMINE OXIDASE B INHIBITORS
Active ingredient group (AIG) number: 0131374001; AHFS:
APPROVED
1997-02-13
Page 1 of 29 PRODUCT MONOGRAPH PR SELEGILINE SELEGILINE HYDROCHLORIDE TABLETS USP (L-DEPRENYL HYDROCHLORIDE TABLETS USP) 5 MG ANTIPARKINSONIAN AGENT AA PHARMA INC. 1165 CREDITSTONE ROAD, UNIT 1 VAUGHAN, ONTARIO L4K 4N7 DATE OF REVISION: MARCH 19, 2021 SUBMISSION CONTROL NO: 249480 Page 2 of 29 PRODUCT MONOGRAPH Pr SELEGILINE Selegiline Hydrochloride Tablets USP (I-Deprenyl Hydrochloride Tablets USP) 5 mg THERAPEUTIC CLASSIFICATION Antiparkinsonian Agent ACTIONS AND CLINICAL PHARMACOLOGY Selegiline hydrochloride is an irreversible inhibitor of the enzyme monoamine oxidase (MAO). Because selegiline has greater affinity for type B than type A MAO, it can serve as a selective inhibitor of MAO-B if it is administered at the recommended dose. Selegiline may have pharmacological effects unrelated to MAO-B inhibition. There is some evidence that it may increase dopaminergic activity by interfering with dopamine re-uptake at the synapse. Effects resulting from selegiline administration may also be mediated through its metabolites. Two of its three principle metabolites, amphetamine and methamphetamine, have pharmacological actions of their own, they interfere with neuronal re-uptake and enhance the release of several neurotransmitters (e.g., norepinephrine, dopamine, serotonin). The extent to which these neurotransmitters contribute to selegiline’s effects are unknown. Rationale for the use of selective MAO-B inhibitors in Parkinson’s Disease Many of the prominent symptoms of Parkinson’s Disease are due to a deficiency of striatal dopamine that is the consequence of a progressive degeneration and loss of a population of dopaminergic neurons which originate in the substantia nigra and project to the striatum. Early in the course of the disease, the deficit in the capacity of these neurons to synthesize dopamine can Page 3 of 29 be overcome by the administration of exogenous levodopa. After several years of levodopa therapy, the response to a given dose of levodopa is often accompanied by side effects (dyskinesia, on- Read the complete document